Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer.

Yan Chen; Email: Yanc99@sinacom; Wei Peng; Yanfang Huang; Jin Chen; Guangjian SU; Chuanhui Jiang; Yanping Xiao

Return

Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer.

Author: Yan CHEN ^{1
,

2} ; Email: YANC99@SINA.COM. ; Wei PENG ³ ; Yanfang HUANG ³ ; Jin CHEN ³ ; Guangjian SU ³ ; Chuanhui JIANG ³ ; Yanping XIAO ³
Author Information

1. Clinical Laboratory Department of Fujian Tumor Hospital, Fujian Medical University, Fuzhou 350014, China
2. Email: yanc99@sina.com.
3. Clinical Laboratory Department of Fujian Tumor Hospital, Fujian Medical University, Fuzhou 350014, China.
Publication Type:Journal Article
MeSH: Adenocarcinoma; blood; enzymology; secondary; Antigens, Neoplasm; blood; Brain Neoplasms; secondary; Carcinoembryonic Antigen; blood; Carcinoma, Large Cell; blood; enzymology; secondary; Carcinoma, Non-Small-Cell Lung; blood; enzymology; secondary; Carcinoma, Squamous Cell; blood; enzymology; secondary; Humans; Keratin-19; blood; Leukocyte Count; Lung Neoplasms; blood; enzymology; pathology; Phosphopyruvate Hydratase; blood; Prognosis; Retrospective Studies; Serum Albumin; analysis
From: Chinese Journal of Oncology 2015;37(7):508-511
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo explore the value of serum neuron-specific enolase (NSE) before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer (NSCLC).
METHODSA total of 128 hospitalized patients with advanced NSCLC from Jan 2012 to Mar 2012 were followed up, and their clinicopathological data, serum NSE, carcinoembryonic antigen, cytokeratin 21-1 (cyfra21-1) levels, albumin (ALB), white blood cell (WBC) before treatment were analyzed retrospectively to determine the factors affecting brain metastasis and prognosis of advanced NSCLC.
RESULTSAmong the 128 NSCLC patients, 90 cases were of adenocarcinoma, 30 cases were of squamous cell carcinoma, and 8 cases were of large cell carcinoma. The median levels of pre-treatment NSE, CEA and cyfra21-1 were 13.6 ng/ml, 7.8 ng/ml and 6.1 ng/ml, respectively. The average levels of ALB and WBC were (35.41 ± 5.60) g/L and (8.16 ± 2.53) × 10⁹/ml, respectively. Multi-variate logistic regression analysis showed that serum NSE before treatment was associated with brain metastasis of advanced NSCLC (P = 0.030). Pre-treatment NSE levels were (34.18 ± 28.48) ng/ml in 28 patients with brain metastasis and (13.87 ± 4.49) ng/ml in 98 patients without brain metastasis (P < 0.05). The median survival time were 3.5 months in patients with normal levels of NSE, and 10.7 months in patients with elevated levels of NSE pre-treatment (P < 0.05).
CONCLUSIONSA higher pre-treatment level of NSE is closely correlated with brain metastasis of advanced NSCLC, and can be used as a predictor of brain metastases in advanced NSCLC. High pre-treatment levels of NSE indicate a poor prognosis in advanced NSCLC patients.